Prostate Cancer

Questions discussed in this category

Is prior Ra-223 a contraindication for treatment?

1 Answer available

What can prostate patients do for sexual function while on ADT?

4 Answers available

Would you ever recommend testosterone replacement for men with incomplete T recovery after ADT for prostate cancer?

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

5 Answers available

How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?

1 Answer available

In high or very high risk prostate cancer, do you utilize combined androgen blockade in patients receiving definitive RT?

Do you have a preference for bicalutamide? Can abiraterone be used instead?

6 Answers available

At what PSA level would you consider restaging a patient who was treated with ADT and radiation and had undetectable PSA?

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

2 Answers available

When would you use PSMA PET over conventional imaging for prostate cancer?

Would you use it for initial staging or at time of biochemical recurrence?

2 Answers available

Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?

1 Answer available

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

3 Answers available

Do you consider estrogen patches in treatment of prostate cancer?

2 Answers available

Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

4 Answers available

Can abiraterone or enzalutamide be substituted for bicalutamide to prevent a flare when initiating ADT with a GnRH agonist for metastatic prostate cancer?

1 Answer available

How would you manage prostate cancer in a patient who received prior chemoradiation followed by an APR for rectal cancer?

If a patient is not a surgical candidate, what it the most appropriate treatment?

2 Answers available

Would you give ADT + docetaxel -> darolutamide for a low risk castrate sensitive metastatic prostate cancer patient given ARASENS results?

The trial inclusion criteria was essentially "docetaxel candidate per the treating oncologist"

2 Answers available

Would you consider de-escalating abiraterone in a patient treated with ADT/abiraterone/prednisone for metastatic hormone sensitive prostate cancer who has had an excellent response with undetectable PSA and minimal side effects for over 2 years?

Is there a concern regarding rarer side effect emergence (cardiac, bone, muscle, cognitive) of long term exposure to "maximal" androgen deprivation? I...

2 Answers available

Based on the STAMPEDE trial pooled analysis, which patients with high risk prostate cancer would you add abiraterone for 2 years?

3 Answers available

How does the FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?

When do you order PSMA PET? Will you preferably order Locametz (gallium Ga 68 gozetotide) PET?

1 Answer available

How do PSMA PET positive nodes change your treatment recommendations after RP?

Would you consider boosting the nodes? What dose? Would this change your recommendation for length of ADT?

2 Answers available

How would you treat a patient with prostate cancer with de novo bone and bone marrow metastases with cytopenias?

Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?

1 Answer available

Do you boost involved mesorectal nodes in node positive prostate cancer?

How high would you try to boost those involved nodes if they are in a favorable location with respect to his rectum and small bowel?

4 Answers available

How do you typically prescribe dose to a PTV for standard IMRT plans?

3 Answers available

What are your top takeaways from ASCO GU 2022?

6 Answers available

Would you consider addition of docetaxel to abiraterone and ADT in metastatic hormone senstive prostate cancer patients who progress on ADT and abiraterone?

Would the results of PEACE-1 trial justify this?

2 Answers available

Would you change treatment in a patient with metastatic CRPC on PARP inhibitor with rising PSA but negative Axumin PET scan?

2 Answers available

Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

2 Answers available

Do you hold ADT before work up for prostate cancer when ordering advanced imaging such as PSMA PET?

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out.

2 Answers available

For metastatic prostate cancer, when would you add carboplatin to docetaxel or cabazitaxel?

1 Answer available

What is your preferred therapy for CDK12-altered advanced prostate cancer, outside clinical trial?

Would you treat with PARP inhibitor or Check-Point Inhibitor?

1 Answer available

For men with intermediate or high-risk prostate cancer, can an SBRT boost be used in place of a brachytherapy boost after EBRT?

3 Answers available

Do you recommend ADT or other systemic therapy in patients with rising PSA after prostatectomy and salvage RT and PSMA scan negative for metastatic disease?

2 Answers available

Do you account for dose from previous Lu-177 treatment for definitive prostate cancer treatment?

Per lutathera information, a patient who had previous treatment for describes an estimated radiation absorbed dose of 12.8 Gy to the bladder. Would yo...

1 Answer available

How would you treat a patient with Gleason 8 or 9 prostate cancer, pretreatment PSA 15-24, with retroperitoneal adenopathy?

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

4 Answers available

How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

1 Answer available

Would you consider PARP inhibition in a patient with metastatic prostate cancer and a germline BRCA2 variant of unknown significance?

Or would you restrict such treatment to patients with known pathogenic germline BRCA mutations?

1 Answer available

In addition to ADT, how would you treat Gleason 8, pure ductal prostate adenocarcinoma with oligometastatic disease?

Given ductal histology, is docetaxel preferred over NHT?

1 Answer available

Is there an absolute PSA level above which you would not recommend a radical prostatectomy for newly diagnosed prostate cancer despite the absence of metastatic disease with advanced imaging?

Are there other high or very high risk features that would also contribute to your decision making?

1 Answer available

Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease. Prostate MRI pending.

2 Answers available

Will you consider adding an AR targeted agent to ADT for a patient thought to have isolated pelvic nodal recurrence of prostate CA if next generation imaging reveals additional non-regional disease not seen on conventional imaging?

Patient previously had prostatectomy and salvage RT

1 Answer available

Would you continue or switch therapy for someone who progressed through AR directed therapy and has a rapid rise in PSA while receiving Ra-223 for bone-dominant castrate resistant prostate cancer?

1 Answer available

What is the best approach to organ confined squamous cell cancer of the prostate?

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

1 Answer available

Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

2 Answers available

How exactly would you utilize ADT via leuprolide or bicalutamide with salvage RT post prostatectomy with PSA >0.5?

2 Answers available

How would you manage a patient with favorable intermediate prostate cancer patient who obtains a high Decipher test score at the end of their RT course?

Would you consider adding ADT?

1 Answer available

Would you treat pelvic lymph nodes in your salvage prostate patient after RP without adverse features due to a limited/no pelvic lymph node sampling?

For the purpose of this question, please assume an initially undetectable post-prostatectomy PSA, no presence of positive margins, extracapsular exten...

1 Answer available

How do you treat localized prostate cancer with neuroendocrine differentiation?

4 Answers available

When do you use a rectal spacer in combination with radiotherapy for prostate cancer?

Are there certain situations where a hydrogel spacer is most useful based on treatment modality (SBRT, protons, brachy, etc) or other factors?

2 Answers available

How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

2 Answers available

What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?

1 Answer available

How would you treat high risk prostate adenocarcinoma who relapsed after RT and ADT with a very low PSA, widespread mets to bone and soft tissue who is progressing on ADT, docetaxel and carboplatin?

No targetable mutations detected

1 Answer available

How would you treat a patient with newly diagnosed prostate cancer with low volume bone metastases and extensive lung metastases with a very low PSA (< 5) and no neuroendocrine differentiation on pathology?

In addition to ADT, would you treat with abiraterone, enzalutamide or docetaxel? Or other treatment - platinum/taxane?

3 Answers available

How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?

2 Answers available

Would you consider radical prostatectomy for a young male with unfavorable intermediate risk cT3a prostate cancer and PSMA PET concerning for regional lymph nodes involvement but negative conventional imaging?

Gleason 4+3=7 and PSA 4

3 Answers available

What are your treatment recommendations in a patient with de novo metastatic prostate adenocarcinoma with neuroendocrine differentiation?

1 Answer available

Do you consider tertiary grade pattern, LVI or PNI on prostatectomy specimens as adverse features to recommend EBRT and ADT for patients with unfavorable intermediate prostate CA after prostatectomy with undetectable PSA?

Are there other adverse features aside from seminal vesicle invasion, positive margins, or extraprostatic extension that you consider?

1 Answer available

After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?

Does post docetaxel PSA influence your decision?

1 Answer available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

How would you sequence therapies for a patient with chemotherapy-naive metastatic castration-resistant prostate cancer who is MSI-H on tissue-based NGS?

What line would you give pembrolizumab?

1 Answer available

Would you consider adding abiraterone or docetaxel in patients with high risk prostate cancer whose PSA does not become undetectable after ADT and radiotherapy with castrate level testosterone?

4 Answers available

When using active surveillance for rising PSA after prostatectomy, at what level of PSA would you start ADT?

2 Answers available

Are there any clinical scenarios where you would recommend adjuvant docetaxel for localized prostate cancer?

1 Answer available

What duration of ADT do you recommend for a patient with locally treated prostate cancer who undergoes metastasis-directed radiation therapy to a single oligometastatic bone lesion?

Would you add abiraterone or enzalutamide?

5 Answers available

How do you approach a patient with a radiographically proven recurrence in the prostate bed after prostatectomy?

If a patient who has undergone radical prostatectomy many years previously presents with biochemical failure and is found to have a nodule in the pros...

3 Answers available

How would you manage a male with a prior history of localized prostate cancer s/p radiation to prostate only (two years ago), who now presents with a T1N0 squamous cell carcinoma of the anus?

Would your management change if the prostate and lymph nodes were treated with radiation two years ago?

2 Answers available

Do you recommend prostate RT for patients with metastatic (M1) disease?

A recent NCBD analysis (Rusthoven et al, JCO 2016) suggests that the addition of prostate RT significantly improves survival compared to ADT alon...

8 Answers available

In a patient with metastatic prostate cancer on abiraterone planning to start Radium-223, what is the minimum interval between the last dose of abiraterone and the first dose of Radium?

1 Answer available

What is your preferred treatment approach for a patient who has prostate cancer with disease only in retroperitoneal nodes, experiencing rapid biochemical progression on abiraterone, and who was previously treated with an androgen receptor inhibitor while non-metastatic?

1 Answer available

How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

2 Answers available

In what settings is Fluciclovine (Axumin) PET/CT best utilized in prostate cancer?

What clinical scenario(s) do you find results to be the most beneficial?

1 Answer available

Would you treat a patient with refractory, metastatic castrate resistant prostate cancer who has somatic ATM mutation with a PARP inhibitor?

Does the specimen (blood vs tissue) used to detect mutation affect your consideration?

1 Answer available

For patients with high-risk metastatic castration-sensitive prostate cancer who have completed upfront ADT + docetaxel, would you consider starting abiraterone or enzalutamide in addition to ADT while the disease is still castration-sensitive?

Are there particular populations in whom you would add an AR targeted agent after docetaxel?

6 Answers available

How should the results of molecular/genetic tests for prostate cancer, be utilized in the post-prostatectomy setting?

There is a recent publication that nicely summarizes the molecular/genetic tests for prostate cancer (https://www.ncbi.nlm.nih.gov/pubmed/26123120). W...

2 Answers available

Which of the androgen blocking agents have the best CNS penetration for someone with metastatic CRPC with brain metastases?

Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

1 Answer available

Which patients would you treat with relugolix instead of injectable GnRH agonist therapy?

HERO study - https://clinicaltrials.gov/ct2/show/NCT03085095

1 Answer available

What is your treatment approach for metastatic squamous carcinoma of the prostate?

1 Answer available

How do you decide between abiraterone or docetaxel for first line treatment of newly diagnosed metastatic prostate cancer?

Given that ADT + abiraterone and ADT + docetaxel have not been directly compared.

2 Answers available

Would you introduce AR targeted therapy if a patient has already been successfully treated with LHRH for low risk, low volume metastatic hormone sensitive prostate cancer?

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

2 Answers available

Would you treat prostate cancer with hormone sensitive metastatic recurrence (after local treatment) the same as de novo metastatic hormone sensitive disease?

1 Answer available

Do you offer adjuvant chemotherapy or abiraterone for patients with high and very high risk prostate cancer with still detectable PSA after radical prostatectomy and lymph node dissection?

2 Answers available

Would you retreat a patient with docetaxel for metastatic castrate resistant prostate cancer if treated in hormone sensitive setting (metastatic disease) with good response three years ago but now has CRPC and has progressed on abiraterone?

2 Answers available

What is the preferred steroid regimen for metastatic prostate cancer patients on docetaxel?

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

1 Answer available

Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?

Is there data and FDA approval for this indication? What about for nodal failure after radiation?

1 Answer available

How would you deliver salvage prostate bed radiation in a patient with a neobladder?

What dose constraint would you use for the neobladder? Small bowel constraint of 54Gy? Or would you recommend observation or ADT alone or low dose RT ...

1 Answer available

Would you treat a patient with Radium 223 for prostate cancer with mainly bone metastasis if he has a history of osteonecrosis of the jaw bone from bisphosphonate/Denosumab?

1 Answer available

How do you think about management options in a patient with a minute focus of Gleason grade 4 (4+4) on 1 core from needle biopsy along with only Gleason 3+3 disease in other biopsy cores and PSA<10?

Assuming patient is not a surgical candidate and wishes to pursue definitive radiotherapy, what duration of ADT would you give?

1 Answer available

How would you treat a patient with metastatic small cell of the prostate who is progressing on cisplatin/etoposide and has previous NGS without actionable mutations?

2 Answers available

Would you treat unfavorable intermediate risk prostate cancer in the setting of recently resected NSCLC?

How would a much higher risk cancer affect decision making? How would you treat him?

3 Answers available

Is there a role of definitive radiation or prostatectomy, in a patient who has M0 castrate resistant prostate cancer and whose PSA is undetectable on ADT and enzulatamide?

2 Answers available

What is your approach to imaging for localization of biochemical relapse of prostate cancer after radical prostatectomy?

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging. Are you utilizing these speciali...

1 Answer available

For recurrent prostate cancer after definitive radiation, how do you guide patients between the various salvage options vs ADT?

1 Answer available

How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

1 Answer available

In a patient with M0CRPC with PSA doubling time < 6 months, will you wait until the absolute PSA value is >2, or is PSADT alone sufficient to start an AR targeted agent?

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

3 Answers available

What is the optimal duration of ADT for cN1 disease with EBRT?

3 Answers available

Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

2 Answers available

Would you skip adjuvant RT in post prostatectomy patients?

Based on the RADICALS-RT trial presented at ESMO, can RT be omitted in post op prostate patients in favor of salvage RT? If not which group of patient...

6 Answers available

What duration of ADT do you recommend for patients with high risk or very high risk prostate cancer who undergo radical prostatectomy, adjuvant RT, and adjuvant docetaxel?

1 Answer available

Would you offer salvage radiation for biochemically recurrent prostate cancer with a transplanted pelvic kidney?

Will your recommendation change if there is suspicious/confirmed locally recurrent nodule in the prostate bed?

3 Answers available

For a very high risk prostate cancer with relatively no elevation in PSA but no distant or nodal metastasis would you consider “neoadjuvant” ADT and chemotherapy prior to EBRT?

In this case, Gleason 5+5 in all cores, clinical T4.

1 Answer available

In a patient with intermediate risk castration sensitive prostate cancer S/P prostectomy and now with biochemical recurrence + regional lymph node involvement 8 months post RP, would you do hormonal therapy (ADT or ADT+Abiraterone) with or without EBRT?

1 Answer available

Should enzalutamide be given concurrently with Sip-T in castration-resistant metastatic prostate cancer?

2 Answers available

Would you offer modest hypofractionation (e.g. 70 Gy/28 fractions) to a patient with intermediate risk prostate cancer and celiac disease?

1 Answer available

How do you manage androgen deprivation in a patient with oligometastatic prostate cancer in which the primary and all known metastatic sites have been treated with curative intent radiation and PSA remains undetectable?

How long would you continue androgen deprivation after radiation?

2 Answers available

Are the cardiac risks of LHRH agonists also seen in patients undergoing bilateral orchiectomy for ADT in hormone-sensitive prostate cancer?

1 Answer available

Has the role of radium-223 changed in the treatment of prostate cancer given the availability of newer anti-androgen medications to treat metastatic prostate cancer?

2 Answers available

How would you treat a patient with metastatic castration resistant prostate adenocarcinoma with progressive neuroendocrine differentiation?

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

1 Answer available

Would you recommend Radium-223 for extensive bone disease in a prostate cancer patient with adenopathy >3cm?

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

1 Answer available

Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

4 Answers available

How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?

1 Answer available

Do you deliver prostate SBRT every other day or consecutively?

Is there a benefit to one fractionation schedule v. the other?

3 Answers available

For a patient with metastatic castration-resistant prostate cancer to the bones with rising PSA but no evidence of radiographic or symptomatic progression, would you continue with the same treatment or change therapy based on biochemical progression?

Assuming there was an initial period of response to the mCRPC treatment.

1 Answer available

Would you use abiraterone or docetaxel in addition to ADT and radiotherapy for patients with very high risk, node-negative prostate cancer?

2 Answers available

In patients who initially received chemo-hormonal first-line therapy for metastatic prostate cancer followed by abiraterone/enzalutamide for castration-resistant disease, would you re-challenge with docetaxel?

Or would you proceed with cabazitaxel or other therapy? Initial chemo-hormonal therapy was ADT + Docetaxel x6 cycles. Docetaxel rechallenge at time o...

2 Answers available

Would you add atezolizumab to carboplatin + etoposide for small cell/neuroendocrine prostate cancer?

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

1 Answer available

How do you manage surveillance imaging for patients with metastatic castration-resistant prostate cancer?

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

1 Answer available

How would you approach an isolated prostate recurrence of high-risk prostate cancer following definitive EBRT?

4 Answers available

Is it appropriate to use photon energies above 15 MV for prostate SBRT?

Do we need to really worry about neutron contamination?

7 Answers available

In a patient who requires prostate cytoreduction prior to EBRT or brachytherapy, do you include a 5-alpha reductase inhibitor in your ADT regimen?

1 Answer available

How would the presence of active rheumatoid arthritis on methotrexate impact your choice of fractionation for a patient with prostate cancer?

1 Answer available

How do you treat newly diagnosed low volume metastatic hormone sensitive prostate cancer in light of new data from STAMPEDE presented at ESMO 2018?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

1 Answer available

How do you manage hot flashes in men with prostate cancer on androgen deprivation therapy?

14 Answers available

In view of possible equivalent efficacy of low dose abiraterone with food, has anyone had clinical experience offering low dose abiraterone to spare patients from financial toxicity of abiraterone?

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

1 Answer available

How do you determine dose for prostate SBRT?

Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?

2 Answers available

Is it acceptable defer or forgo biopsy and to start androgen deprivation therapy in an elderly, fragile patient with PSA in the 900s and evidence of bone metastases?

1 Answer available

When is the best time to start denosumab in men with metastatic prostate cancer?

Should it be started at the initial diagnosis of bone mets?

2 Answers available

How do you approach non-metastatic castration-resistant prostate cancer?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

2 Answers available

How would you approach a patient with M0 castrate-resistant prostate cancer started on enzalutamide who continues to have increasing PSA levels without metastases seen on imaging?

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

1 Answer available

How do you manage a patient with metastatic prostate cancer who does not acheive a PSA response to upfront ADT?

1 Answer available

How do you approach a patient with a non-castrate testosterone level and rising PSA despite receiving LHRH agonist therapy?

1 Answer available

What dose and fractionation is safe to use for palliation of a large pelvic mass several years after definitive prostate brachytherapy?

1 Answer available

What is the optimal duration of ADT in high-risk prostate cancer treated with RT+ADT?

Based on the updated results of the PCS IV trial is 18 months of ADT the new standard of care for men with high-risk prostate cancer treated with...

4 Answers available

Would you use AR-V7 testing to decide second-line androgen receptor-axis-targeted therapy vs chemotherapy for patients who with metastatic castration-resistant prostate cancer?

If yes, what factors push you to test for AR-V7 or would you test all patients in this clinical scenario?

3 Answers available

What approach would you take for patients with metastatic castration-resistant prostate cancer with marked PSA response (undetectable) on docetaxel, but radiographic progression in bone metastases?

1 Answer available

How would you treat a patient with high-volume metastatic prostate cancer who has asymptomatic biochemical relapse after having a good response to upfront docetaxel?

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

1 Answer available

Is ADT alone appropriate for high risk prostate cancer patients without evidence of metastasis and limited life expectancy?

Is there data to support this practice, which appears in the NCCN guidelines?

1 Answer available

What dose constraint(s) would you use for a patient with a pelvic kidney transplant getting pelvic RT?

1 Answer available

For what patient groups (if any) do you routinely recommend screening colonoscopy prior to radiation for prostate cancer?

3 Answers available

When do you offer salvage prostate bed RT to patients who have a biochemical recurrence >5 years after RP?

In the case of patients many years out from RP who have a slowly rising PSA, do you offer salvage RT while the PSA is still very low or follow the PSA...

1 Answer available

How do you manage musculoskeletal pain in men receiving androgen deprivation therapy for non-metastatic prostate cancer?

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

1 Answer available

If a patient with non-metastatic prostate cancer is found to have a BRCA mutation, should this influence treatment recommendations for local therapy?

2 Answers available

What is your approach to patients with locally recurrent prostate cancer following cryotherapy or HIFU?

With biopsy-proven, negative systemic restaging disease, what dose and fractionation is appropriate if treating with IMRT? Should ADT generally b...

1 Answer available

Does a transitional zone vs. peripheral zone location of low risk prostate cancer affect your recommendation for active surveillance?

1 Answer available

Do you treat pelvic lymph nodes in patients with high-risk prostate cancer who refuse ADT?

Would you consider this an indication to treat lymph nodes, if you would typically not do so?

2 Answers available

Should definitive radiotherapy and ADT be offered to patients with PSA > 100 who have no evidence of metastatic disease?

Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?

6 Answers available

What imaging workup should be completed in patients with a detectable PSA following prostatectomy?

Should the workup change with the PSA level (for example, >2 vs <2 ng/ml post-op PSA)? Is there a PSA level for which salvage radiotherapy...

2 Answers available

Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

3 Answers available

When do you initiate androgen deprivation therapy for biochemical relapse of prostate cancer following primary therapy?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

1 Answer available

Do you treat with high-dose radiation alone (without ADT) for favorable intermediate risk prostate cancer?

If so, what criteria do you use to guide your decision?

3 Answers available

How do you define PSA progression after salvage or adjuvant prostate fossa radiotherapy?

In the recent 10 year update of the ARO (adjuvant pelvic RT versus observation) trial, their definition of PSA failure was 2 successive rise...

3 Answers available

What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?

Do other factors (i.e. Gleason score, pretreatment PSA, or pT stage) affect your decision?

2 Answers available

In light of CHAARTED and STAMPEDE, should all men with newly-diagnosed, treatment-naive metastatic prostate cancer be treated with chemohormonal therapy?

1 Answer available

What criteria do you use when considering treating the pelvic nodes in a salvage prostatectomy case versus covering only the postoperative bed?

Would a specific Gleason score, age, pathological feature, or PSA be an indication for covering the pelvic nodes? Would giving concurrent ADT affect y...

3 Answers available

Which, if any, aspects of your management of prostate cancer differ in your African-American patients versus those of other racial/ethnic backgrounds?

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

1 Answer available

At what PSA do you initiate ADT for a biochemical recurrence after prostate radiotherapy (adjuvant, salvage, or definitive)?

Does PSADT play a factor in your decision-making? If so, how specifically? I've tended to wait until the PSA is 10-15, re-image, and then begin...

1 Answer available

For patients eligible for and considering active surveillance for low-risk prostate cancer, do you routinely use tests for molecular risk stratification?

Are there specific subsets for whom these results should change management?

1 Answer available

Do you routinely offer AR-v7 testing to determine whether to treat with chemotherapy versus enzalutamide or abiraterone in metastatic castration resistant prostate cancer?

2 Answers available

Do you routinely include sipuleucel-T as one of your lines of systemic therapy for metastatic castration resistant prostate cancer?

If so, how do you sequence this with other therapies? In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

1 Answer available

Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

1 Answer available

For castration-naive metastatic prostate cancer patients who you plan to treat with LHRH agonist monotherapy, how long do you treat with an anti-androgen therapy prior to and after initiating the LHRH-agonist?

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

1 Answer available

Is there a role for adjuvant docetaxel in patients with high-risk localized prostate cancer who elect for prostatectomy?

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521. Following prostatectomy,...

1 Answer available

Following presentation of the PRINCE at ASCO 2016, should we be offering intermittent docetaxel to patients with metastatic castration-resistant prostate cancer?

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

1 Answer available

When should intermittent androgen deprivation vs continuous androgen deprivation be used for the treatment of prostate cancer?

In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

1 Answer available

Is there any role for radium-223 early in the course of castration-resistant prostate cancer with bone metastases?

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies. Is there a population of men w...

1 Answer available

When does a rising PSA after prostatectomy indicate growth just of normal prostate?

Guidelines dont seem to account for this possibility. Could it just be normal prostate tissue growing back that is leading to PSA, why just assume it ...

1 Answer available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answer available

How do you manage high risk prostate cancer patients with well controlled Crohn's disease?

Do you offer RT if the patient is well controlled on medications?

2 Answers available

What are the most common errors that can be made when performing prostate SBRT?

In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?

2 Answers available

At what point would Radium-223 dicholoride treatment be the best management for a patient with established metastatic prostate cancer with an elevated PSA and symptomatic bone pain with corresponding bone lesions on imaging?

1 Answer available

For biochemical failure following prostatectomy, is there a PSA value that would be considered too high to offer local salvage radiotherapy?

On what other factors should be considered in making a treatment recommendation for salvage radiation therapy?

3 Answers available

When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

2 Answers available

At what PSA do you start calculating doubling time post-prostatectomy?

With ultra-sensitive PSA, it's unclear to me whether a doubling from 0.01 to 0.02 or 0.02 to 0.04 is significant. Is there a certain value that you wo...

1 Answer available

How long should the duration of hormones be in post-prostatectomy patients receiving salvage RT?

If a patient is deemed high risk enough to require hormones with RT in the salvage setting, how long would you maintain them on ADT? Would you extrapo...

2 Answers available

Do you forgo adjuvant radiotherapy for men with pT3 prostate cancer who have significant urinary incontinence?

Would you favor only offering salvage therapy if the PSA rises?

5 Answers available

What is the best toxicity data to quote to patients for prostate IMRT vs nerve-sparing prostatectomy?

When counseling patients with organ-confined prostate cancer, what rates of impotence, incontinence, rectal toxicity, and urethral stricture shou...

2 Answers available

What is the minimum amount of time you should wait between a TURP and the start of definitive prostate radiation therapy?

2 Answers available

Should prostate cancer genomic classifiers, such as Decipher, be used in all high risk post-prostatectomy patients to risk stratify patients to adjvant RT vs PSA observation and possible salvage RT?

The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, g...

1 Answer available

What is the appropriate treatment for a low lying rectal cancer in the setting of prior definitive prostate IMRT?

Fore example for a T3N0 rectal cancer on EUS?

1 Answer available

What is the best approach to management of newly diagnosed intermediate or high risk prostate cancer in a patient with high grade non-muscle invasive bladder cancer?

In this case, the patient is currently on maintenance BCG.

1 Answer available

Do you feel that HDR brachytherapy alone is adequate treatment for some intermediate-risk prostate cancer patients?

If so, what selection criteria do you use for such patients?

2 Answers available

For which patients with localized prostate cancer is SBRT an alternate standard of care?

1 Answer available

Is there an age that is too young for prostate irradiation?

Do you use a particular cut-off? For example, someone in their 40's?

3 Answers available

Is it acceptable to use SBRT for prostate bed RT?

If so, what dose?

2 Answers available

Would you treat radio-graphically positive pelvic lymph nodes when palliating a patient with metastatic patient prostate cancer and obstructive symptoms?

The patient has a positive bone scan (2 lesions), grade 4+5=9/10 prostate, and cancer cannot urinate without a catheter.

1 Answer available

Should prophylactic breast radiotherapy still be practiced for patients with prostate cancer taking bicalutamide?

1 Answer available

For intermediate risk prostate cancer do you recommend short-term complete androgen blockade or LHRH agonist alone?

2 Answers available

If one decides to use a mpMRI to stage a pt with low-risk prostate cancer, how do you work up a focal lesion suspicious for higher grade GS 7-10 disease?

1 Answer available

Which patients with intermediate and high risk prostate cancer should not receive androgen deprivation therapy?

More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?

2 Answers available

For patients with high risk prostate cancer, is there data to support increased morbidity, such as increased urethral strictures or cystitis, when given postprostatectomy XRT as opposed to definitive XRT?

In general how do you counsel patients with high risk prostate cancer when choosing radiation verse prostatectomy? What numbers do you quote for ...

4 Answers available

Would you consider offering salvage radiation to a patient with castrate resistant prostate cancer who has never had local therapy and has no evidence of lymph node or distant metastasis?

This is a patient who would have been an appropriate candidate for radiation upfront, but was managed with androgen deprivation therapy instead. On th...

2 Answers available

If a daily conebeam CT is done for prostate cancer treatments, do you subtract any treatment fractions to compensate for the daily imaging dose?

1 Answer available

What is your technique for CT and MRI fusion for external beam prostate planning?

Sometimes the scans don’t line up well because of differences in rectal and bladder fullness- any tips to optimize the fusion?

1 Answer available

Would you treat a patient who failed cryotherapy?

1 Answer available

For patients with high risk prostate cancer, is there data to support prostatectomy, as opposed to upfront RT?

I ask this because I am seeing more and more patients who have had surgery despite presenting with high risk disease.

1 Answer available

In a low volume prostate cancer (2 of 12 cores, low percentage) with a GS 4+4=8, how long does ADT need to be administered?

1 Answer available

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?

I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage?

1 Answer available

What fractionation and dose constraints do you use for prostate SBRT?

1 Answer available

Do you decrease the duration of hormones in a man with high risk prostate cancer and cardiac risk factors?

3 Answers available

What's the safest way to hypofractionate treatment for prostate cancer?

1 Answer available

What is your management strategy for patients with positive lymph nodes after radical prostatectomy?

2 Answers available

Do HIV/AIDS patients with prostate cancer have increased radiation toxicity?

And should special precautions be taken (such as dose reduction, prophylactic symptom management, etc)?

1 Answer available

What is your institution's active surveillance protocol?

1 Answer available

How should I interpret a Gleason 7 prostate cancer (4+3 or 3+4) with tertiary grade 5?

Would you treat this as high risk?

1 Answer available

Is there any data to support the use of hormone therapy with RT in the adjuvant post-prostatectomy setting?

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2005-04-01

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Int J Radiat Oncol Biol Phys, 2005 Sep 1

Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.

International journal of radiation oncology, biology, physics, 2004-06-01

Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?

International journal of radiation oncology, biology, physics, 2007-08-01

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

International journal of radiation oncology, biology, physics, 2014-04-01

Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Int. J. Radiat. Oncol. Biol. Phys., 2012-12-01

Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.

European urology, 2013-12

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

CA Cancer J Clin, 2010 May-Jun

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

J Natl Cancer Inst, 2010 Jan 6

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

BJU international, 2014-12

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

JAMA, 2011-12-07

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Cancer, 2013 May 15

Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

International journal of radiation oncology, biology, physics, 2010-11-01

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

American journal of clinical oncology, 2016-02

Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey.

Radiother Oncol, 2013-01-01

Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-20

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Eur. Urol., 2009-05-01

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

The American journal of surgical pathology, 2005-09

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

The New England journal of medicine, 2012-07-19

Radical prostatectomy versus observation for localized prostate cancer.

BMJ, 2014-01-08

Prostate cancer: summary of updated NICE guidance.

International journal of radiation oncology, biology, physics, 2012-05-01

Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients.

International journal of radiation oncology, biology, physics, 2012-02-01

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

N. Engl. J. Med., 2009-06-11

Duration of androgen suppression in the treatment of prostate cancer.

JAMA, 2006-11-15

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Practical radiation oncology, 2013

Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients.

N Engl J Med, 2008 Mar 20

Quality of life and satisfaction with outcome among prostate-cancer survivors.

The Journal of urology, 2011-09

Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.

Practical radiation oncology, 2013

Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life.

Urologic oncology, 2014-04

Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.

BJU international, 2014-03

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

J. Urol., 1998-01-01

Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study.

Eur. Urol., 2014-03-01

Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.

BJU international, 2015-10

Preoperative predictive model of recovery of urinary continence after radical prostatectomy.

The New England journal of medicine, 2011-07-14

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

International journal of radiation oncology, biology, physics, 2010-04

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

JAMA, 2015

Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.

The Journal of urology, 2012-01

High dose brachytherapy as monotherapy for intermediate risk prostate cancer.

International journal of radiation oncology, biology, physics, 2013-03-15

Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Cancer, 2014-06-15

The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.

Cancer, 2006 Jun 15

Does age matter in the selection of treatment for men with early-stage prostate cancer?

International journal of radiation oncology, biology, physics, 2003-03-15

Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.

Urology, 2008-11

CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Eur. Urol.,

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

American journal of clinical oncology, 2014-06

Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review.

International journal of radiation oncology, biology, physics, 2011-07-15

External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS).

International journal of radiation oncology, biology, physics, 2010-07-15

External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.

Frontiers in oncology, 2011

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-04

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-20

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.

The New England journal of medicine, 2017-02-02

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

JAMA Oncol, 2017-10-01

Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.

Seminars in radiation oncology, 2013-07

Adjuvant versus salvage radiotherapy for high-risk prostate cancer patients.

Eur Urol, 2015 Jul 16

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

BJU Int, 2009 Feb

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

European urology, 2014-06

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-20

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

The New England journal of medicine, 2013-07-18

Alpha emitter radium-223 and survival in metastatic prostate cancer.

JAMA Oncol, 2020 Aug 27

Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

European urology, 2011-04

The prognostic significance of capsular incision into tumor during radical prostatectomy.

Urology, 2001-11

Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

The New England journal of medicine, 2004-10-07

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

JAMA oncology, 2016-11-01

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

J. Nucl. Med., 2015 Jun 25

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 23

Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.

Brachytherapy, 2020 Apr 21

Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.

Int. J. Radiat. Oncol. Biol. Phys., 2020 Jan 24

Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

Lancet Oncol., 2010-02-01

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

The Journal of urology, 2005-08

Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

The Journal of urology, 1999-07

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

The New England journal of medicine, 2018-05-03

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

The Journal of urology, 2002-09

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Nature, 2005-12-08

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

J Clin Oncol, 1999 Jul

Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.

Lancet, 2015 Jan 3

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

The New England journal of medicine, 2001-12-06

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Lancet, 2001-09-22

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Breast Cancer Res. Treat., 2010-02-01

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

The Journal of urology, 1982-06

Treatment of a metastatic prostate derived tumor with surgery and chemotherapy.

Cancer research, 2000-04-15

Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction.

J. Clin. Oncol., 2009-04-01

Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.

Oncol. Rep., 2015-12-01

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.

Nat Commun, 2015-04-01

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

PLoS ONE, 2016-01-01

Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

J. Urol., 2002-04-01

Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.

Lancet Oncol., 2015 Sep 09

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

European urology, 2018-02

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Lancet, 2018 Oct 18

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

The New England journal of medicine, 2015-08-20

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

JAMA, 2008-06-18

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

International journal of radiation oncology, biology, physics, 2007-11-01

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

The Lancet. Oncology, 2006-06

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

JAMA oncology, 2016-04

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

JAMA oncology, 2017-01-01

Association Between Androgen Deprivation Therapy and Risk of Dementia.

The New England journal of medicine, 2018-04-12

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

The New England journal of medicine, 2018-06-28

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Int J Radiat Oncol Biol Phys, 2012 Jul 15

Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen.

International journal of radiation oncology, biology, physics, 2011-06-01

Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.

Lancet, 2008 Dec 16

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Lancet, 2011-12-17

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Urology, 2017-04

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

Int J Radiat Oncol Biol Phys, 1986 Mar

Extended field (periaortic) irradiation in carcinoma of the prostate--analysis of RTOG 75-06.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol,

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

J Urol,

Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.

Frontiers in oncology, 2017

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

International journal of radiation oncology, biology, physics, 2008-09-01

Intrafractional motion of the prostate during hypofractionated radiotherapy.

European urology, 2018-07

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

International journal of radiation oncology, biology, physics, 2008-04-01

Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.

International journal of radiation oncology, biology, physics, 2014-07-01

Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.

International journal of radiation oncology, biology, physics, 2016-07-01

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11

Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Frontiers of radiation therapy and oncology, 2011

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.

Semin Radiat Oncol, 2016 Aug 31

Options for Salvage of Radiation Failures for Prostate Cancer.

Urology, 2013-06

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

J. Clin. Oncol., 2015 May 26

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

J. Clin. Oncol.,

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

Nat Rev Urol, 2014 Apr

Small cell carcinoma of the prostate.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

International journal of radiation oncology, biology, physics, 2012-04-01

High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT.

Brachytherapy, 2016

Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.

N Engl J Med, 2010 Jul 29

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-03-15

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Prostate Int,

Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice.

Practical radiation oncology, 2018

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.

Practical radiation oncology, 2018

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Low-Fat Abiraterone Food Effect Is of Little Consequence.

Nat Rev Urol, 2017 Dec 12

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.

Journal of contemporary brachytherapy, 2016-10

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.

International journal of radiation oncology, biology, physics, 2012-07-01

Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.

Radiother Oncol, 2009 Apr

Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy.

Lancet, 2021 Dec 23

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Ann. Oncol.,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

The Lancet. Oncology, 2013-08

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

J. Clin. Oncol., 2019 Jul 22

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Lancet Oncol, 2019 Apr 12

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Semin Radiat Oncol, 2004-01-01

Errors and margins in radiotherapy.

Practical radiation oncology, 2017

State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions.

AJR. American journal of roentgenology, 2019-10

Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.

JAMA oncology, 2019-06-01

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Clin Nucl Med,

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

The Lancet. Oncology, 2019-03

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

JAMA Oncol,

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

BJU international, 2012-10

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

European urology, 2018-08

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

N. Engl. J. Med., 2019 Sep 30

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

Lancet,

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Eur. Urol., 2018 Jul 03

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

J. Clin. Oncol., 2017 Dec 14

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Eur. Urol., 2019 Jul 19

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.

J Thorac Oncol. , 2019 Oct 17

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Cancer, 2020 Feb 19

Validation of a subclassification for high-risk prostate cancer in a prospective cohort.

Clin Genitourin Cancer, 2019 Mar 13

Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.

N. Engl. J. Med., 2020 May 29

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?

Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.

BMC Cancer, 2014 Sep 15

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

JAMA Oncol,

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Eur Urol, 2019 Feb 28

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

Urology, 2001-08

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

Lancet Oncol., 2016-06-01

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

JAMA Oncol, 2020 Mar 26

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.

Lancet, 2020 Sep 28

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.

Lancet Oncol,

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

The New England journal of medicine, 2012-09-06

Intermittent androgen suppression for rising PSA level after radiotherapy.

Radiother Oncol, 2020 Apr 01

Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.

The Lancet. Oncology, 2012-02

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.

International journal of radiation oncology, biology, physics, 2016-11-01

Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.

Cancer, 2018-07-15

Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Oncologist, 2020 Dec 03

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.

Urology, 2000-11-01

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.

Abdom Radiol (NY), 2019 Aug 29

Apical periurethral transition zone lesions: MRI and histology findings.

Lancet, 2021 May 07

F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.

N. Engl. J. Med., 2016-10-13

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

J Urol, 2020 Apr 13

Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.

Eur J Nucl Med Mol Imaging, 2020 Aug 12

Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.

J Urol,

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

Lancet Oncol, 2010 Oct 07

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Prostate Cancer Prostatic Dis, 2020 May 13

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

The Lancet. Oncology, 2018-11

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

The Prostate, 2019-09

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

J Urol, 2020 Dec 28

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.

Lancet Oncol, 2020 Mar 27

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Clinical genitourinary cancer, 2018-06

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Cancer treatment and research communications, 2019

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Prostate Cancer Prostatic Dis, 2020 Feb 28

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Cancer, 2019 Dec 1

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Nat Rev Urol, 2021 Apr 06

Optimizing the diagnosis and management of ductal prostate cancer.

Eur Urol, 2020 Dec 03

Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.

J Clin Oncol, 2021 Jan 26

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.

Pancreas, 2010-08

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.

American journal of clinical and experimental urology, 2014

Neuroendocrine differentiation of prostate cancer: a review.

The New England journal of medicine, 2019-03-28

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2019 Sep 11

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.

Lancet Oncol, 2019 Oct 16

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.

JAMA Oncol,

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.

J Urol, 2021 Feb 26

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-05

Intermittent versus continuous androgen deprivation therapy.

Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

European journal of nuclear medicine and molecular imaging, 2018-11

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

European urology oncology, 2018-05

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

J Nucl Med, 2021 Dec 16

Predictors of F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.

J Nucl Med, 2018 Dec 14

Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.

Eur J Nucl Med Mol Imaging, 2019 Nov 15

The effect of androgen deprivation therapy on Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.

Eur J Nucl Med Mol Imaging, 2019 Dec 26

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.

JAMA Oncol,

Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.

J Urol, 2021 Feb 03

The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.

J Nucl Med, 2020 Jan 10

Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

N Engl J Med, 2020 Apr 28

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Prostate cancer and prostatic diseases, 2018-04

Platinum sensitivity in metastatic prostate cancer: does histology matter?

JCO Precis Oncol, 2020

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

Lancet Oncol, 2019 Sep 09

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.

BJU international, 2014-12

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.

The Journal of urology, 2002-09

Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

Lancet, 2020 Sep 28

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.

BMC cancer, 2019-06-13

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

J Clin Oncol, 2022 Mar 15

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.

N Engl J Med, 2022 Feb 17

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Am J Clin Oncol,

Pelvic Reirradiation Utilizing Pulsed Low-dose Rate Radiation Therapy.

Prostate, 2022 Jun 08

The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

Br J Cancer, 2008 Feb 12

Parenteral oestrogen in the treatment of prostate cancer: a systematic review.

Lancet,

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.

Eur Urol, 2015 Dec 17

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

BJU Int, 2016 Nov 12

Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

International journal of radiation oncology, biology, physics, 2006-07-15

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

J Nucl Med, 2021 Jun 24

Lu-Prostate-Specific Membrane Antigen Ligand After Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience.

Oncotarget, 2017 Feb 25

Radioligand therapy of metastatic prostate cancer using Lu-PSMA-617 after radiation exposure to Ra-dichloride.

Practical radiation oncology, 2017

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall.

JAMA Oncol,

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.

BJU Int, 2022 Apr 03

Development and validation of a life expectancy calculator for US patients with prostate cancer.

Int J Radiat Oncol Biol Phys, 2020 Sep 11

Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.

Lancet Oncol, 2022 Jan 17

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

Prostate Int, 2019 Feb 22

The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study.

Prostate Cancer

Questions discussed in this category

Papers discussed in this category

Related Topics